Please assess the completion status of the following clinical trial:

Trial Title: STI571 in Treating Patients With Recurrent Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Recurrent Philadelphia (Ph) chromosome-positive leukemia~  * Recurrent or refractory acute lymphoblastic or myeloblastic leukemia OR~ * Chronic myelogenous leukemia with resistance to interferon alfa with any of the following:~    * WBC at least 20,000/mm\^3 after at least 3 months of interferon therapy~   * At least 100% increase in WBC to at least 20,000/mm\^3 confirmed over 2 weeks while receiving interferon alfa~   * At least 66% Ph chromosome-positive cells after 1 year of interferon therapy~   * At least 30% increase in number of Ph chromosome-positive cells after an interferon-induced response while continuing interferon therapy~PATIENT CHARACTERISTICS:~Age:~* Under 22~Performance status:~* Karnofsky 50-100% if over 10 years of age OR~* Lansky 50-100% if 10 years of age and under~Life expectancy:~* At least 8 weeks~Hematopoietic:~* See Disease Characteristics~Hepatic:~* Bilirubin no greater than 1.5 times normal~* SGPT less than 3 times normal~* Albumin greater than 2 g/dL~Renal:~* Creatinine no greater than 1.5 times normal OR~* Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* If prior allogeneic stem cell transplantation, no uncontrolled graft-versus -host disease~* No seizure disorder if on anticonvulsants~* No uncontrolled infection~* No CNS toxicity greater than grade 2~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Disease Characteristics~* At least 1 week since prior biologic therapy and recovered~* At least 3 months since prior stem cell transplantation (SCT)~* At least 1 week since prior growth factors~* At least 1 week since prior interferon alfa~Chemotherapy:~* Recovered from prior chemotherapy~* At least 6 weeks since prior busulfan and nitrosoureas~* At least 2 weeks since prior homoharringtonine~* At least 1 week since low-dose cytarabine~* At least 2 weeks since prior moderate-dose cytarabine~* At least 4 weeks since prior high-dose cytarabine~* At least 3 weeks since all other prior cytotoxic chemotherapies~* No prior hydroxyurea~Endocrine therapy:~* Must be on a stable dose of steroids if received prior allogeneic SCT~Radiotherapy:~* Recovered from prior radiotherapy~* At least 2 weeks since prior local palliative radiotherapy (small port)~* At least 6 months since prior craniospinal radiotherapy~* At least 6 months since prior radiotherapy to 50% or more of the pelvis~* At least 6 weeks since other prior substantial bone marrow radiotherapy~Surgery:~* Not specified~Other:~* No other concurrent investigational agents~* No concurrent anticonvulsants

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- 260 mg/m2 imatinib mesylate (ST571) (Type: EXPERIMENTAL): None
- 340 mg/m2 imatinib mesylate (ST571) (Type: EXPERIMENTAL): None
- 440 mg/m2 imatinib mesylate (ST571) (Type: EXPERIMENTAL): None
- 570 mg/m2 imatinib mesylate (ST571) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete